JPMorgan has maintained its ‘Overweight’ rating on Cipla, with a target price of ₹1,165, suggesting a potential upside of nearly 30% from the current price of ₹1,663.95. Cipla’s domestic growth outlook remains strong, with a focus on peptides and complex generics in the U.S.
The company is also exploring M&A opportunities, leveraging its solid balance sheet, while navigating supply challenges related to Lanreotide. China is expected to become a key market for Cipla, though it remains in the nascent stage.
Disclaimer: The information provided in this article is for informational purposes only and should not be construed as investment advice. Please consult a financial advisor before making any investment decisions.
